Dabigatran Etexilate in Patients With Mechanical Heart Valves

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 328 participants.

Also called NCT01452347

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 328 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01452347
  • EudraCT 2010-022685-27
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Canada, Czechia, Denmark, France, Germany, Netherlands, Norway, Poland, Sweden (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01452347. Randomized; no masking; primary purpose prevention. Start 2011-10 (registry gives no type); primary completion 2013-06 (actual). Results posted on 2014-08-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dabigatran Etexilate in Patients With Mechanical Heart Valves
Acronym
RE-ALIGN
Condition
Heart Valve Diseases
Intervention (Drug)
warfarin 1mg
Intervention (Drug)
dabigatran etexilate intermediate dose
Intervention (Drug)
dabigatran etexilate low dose
Intervention (Drug)
warfarin 5mg
Intervention (Drug)
dabigatran etexilate high dose
Intervention (Drug)
warfarin 3mg
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct01452347
Content hash
cceaec6f2f867ab97cb60463202009cae62375dee3f0c8eb12eb0de1d6bb459e